力生製藥(002393.SZ)子公司中央藥業實際使用的天津市北辰區富錦道1號地塊擬被收儲
格隆匯1月7日丨力生製藥(002393.SZ)公佈,因城市規劃調整需要,天津市北辰區土地整理中心根據《土地儲備管理辦法》等文件的規定,擬對天津市醫藥集團有限公司(“醫藥集團”)持有的、全資子公司天津市中央藥業有限公司(“中央藥業”)實際使用的天津市北辰區富錦道1號地塊進行協議收儲,收儲範圍包括協議約定的所屬國有土地使用權、建築物、構築物等資產。
由於歷史原因,中央藥業僅擁有北辰區富錦道1號所在地上的房屋、建築物及構築物的所有權,並無其所在地北辰區富錦道1號房屋建築物所佔用土地的土地使用權,該宗地的土地使用者為醫藥集團。
此次收儲的土地面積共計7.3942公頃(110.913畝),依據北京中同華資產評估有限公司(“中同華”)出具的截至評估基準日為2019年10月31日評估報告(中同華評報字(2019)第131394號)醫藥集團和中央藥業資產權屬的評估值為基礎,天津市北辰區土地整理中心同意協議約定此次收儲綜合補償標準200萬元/畝,共計人民幣22182.6萬元整(包括但不限於土地補償、地上(下)建(構)築物、機器設備及其他附着物的補償;整理儲備地塊的場地調查費用;人員安置、搬遷、騰遷、誤工、解除土地和房屋租賃、抵押、查封等關係的補償及財務、相關税費等全部費用)。其中支付給醫藥集團綜合補償費:約1.17億元,支付給中央藥業綜合補償費:約1.05億元。
收儲協議顯示,此次收儲範圍:整理儲備土地位於天津市北辰區富錦道南側,四至範圍東至天津市有機化工一廠;南至盛倉北道;西至高雲路;北至富錦道,佔地面積7.3942公頃(110.913畝)。協議總金額:約2.22億元整。
此次收儲的地塊中央藥業仍可正常使用,公司將積極推進中央藥業在2023年底之前完成搬遷工作,不影響其正常生產經營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.